Belsar-M5 mg+20 mg

Belsar-M 5 mg+20 mg is a fixed-dose combination indicated for the treatment of hypertension (high blood pressure). Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

• Add-on/substitution therapy: For patients whose blood pressure is not adequately controlled on monotherapy with either a calcium channel blocker (such as amlodipine) or an angiotensin II receptor blocker (such as olmesartan) alone.
• Initial therapy: May be used as initial treatment in patients who are likely to need multiple antihypertensive drugs to achieve their blood pressure goals, based on individualized risk assessment by a physician.

Belsar-M 5 mg+20 mg is not indicated for initial therapy in patients whose blood pressure can likely be controlled with a single agent, and it is not approved for use in children.

Each film-coated tablet of Belsar-M 5 mg+20 mg contains amlodipine besilate equivalent to amlodipine (2.5 mg, 5 mg, or 10 mg) combined with olmesartan medoxomil (20 mg or 40 mg). Common commercially available strength combinations include 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg (amlodipine/olmesartan medoxomil).

Belsar-M 5 mg+20 mg combines two antihypertensive agents that work through different but complementary mechanisms: amlodipine, a dihydropyridine calcium channel blocker, and olmesartan medoxomil, an angiotensin II receptor blocker (ARB). By targeting two distinct pathways involved in blood pressure regulation, this combination provides more effective blood pressure control than either agent used alone, and is prescribed for adults with hypertension who require combination therapy.

Combination antihypertensive: Dihydropyridine Calcium Channel Blocker (CCB) + Angiotensin II Receptor Blocker (ARB). Belsar-M 5 mg+20 mg belongs to this fixed-dose combination class.

Belsar-M 5 mg+20 mg lowers blood pressure through two complementary mechanisms:

• Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, relaxing vascular smooth muscle and producing peripheral arterial vasodilation.
• Olmesartan medoxomil is a prodrug rapidly hydrolyzed to olmesartan, the active moiety, during absorption. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.

The combination provides an additive antihypertensive effect compared with either component alone.

Belsar-M 5 mg+20 mg is taken orally, once daily, with or without food. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless advised by a physician. Take the dose at the same time each day. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose - do not double the dose.

Belsar-M 5 mg+20 mg has clinically significant interactions with the following:

• Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: increased risk of hyperkalemia via the olmesartan component; monitor serum potassium.
• Dual blockade of the renin-angiotensin system (e.g., ACE inhibitors, aliskiren): increases risk of hypotension, hyperkalemia, and renal impairment; concomitant use of aliskiren is contraindicated in patients with diabetes.
• NSAIDs (including selective COX-2 inhibitors): may reduce the antihypertensive effect of olmesartan and increase risk of renal impairment, particularly in elderly, volume-depleted, or renally impaired patients.
• Lithium: ARBs may increase serum lithium concentrations and lithium toxicity; monitor lithium levels during concomitant use.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may increase amlodipine plasma concentrations, increasing risk of hypotension and edema.
• Simvastatin: amlodipine increases simvastatin systemic exposure; when combined, simvastatin dose should not exceed 20 mg daily.
• Other antihypertensive agents: additive blood-pressure-lowering effect; monitor for symptomatic hypotension, particularly at treatment initiation.

Common side effects of Belsar-M 5 mg+20 mg include:

• Peripheral edema (swelling of the ankles/feet, dose-related, from the amlodipine component)
• Dizziness and headache
• Symptomatic hypotension, particularly after the first dose or a dose increase
• Flushing and palpitations
• Fatigue
• Hyperkalemia (elevated blood potassium)
• Upper respiratory infection symptoms

Important rare but serious effect: Olmesartan has been associated with a rare condition called sprue-like enteropathy - severe, chronic diarrhea with substantial weight loss, sometimes occurring months to years after starting treatment and often diagnosed only after other causes (such as celiac disease) have been ruled out. Symptoms generally resolve after discontinuing Belsar-M 5 mg+20 mg. Patients who develop unexplained chronic diarrhea and weight loss while on this medicine should seek prompt medical evaluation.

Pregnancy: Belsar-M 5 mg+20 mg is contraindicated during pregnancy. Drugs that act directly on the renin-angiotensin system, such as the olmesartan component, can cause fetal and neonatal injury or death, including oligohydramnios, fetal renal failure, hypotension, skull hypoplasia, and death, when used during the second and third trimesters. If pregnancy is detected, discontinue this medicine as soon as possible and consult a physician immediately for alternative treatment. Women who are planning pregnancy or of childbearing potential should discuss appropriate contraception and alternative antihypertensive therapy with their physician.

Lactation: It is not known whether olmesartan or amlodipine are excreted in human breast milk in clinically significant amounts. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue the medicine, taking into account the importance of treatment to the mother; use only if clearly needed and a physician determines potential benefit justifies potential risk.

Fetal toxicity: See Pregnancy and Lactation - an important safety warning for the olmesartan component.

Sprue-like enteropathy: See Side Effects for a full description of this rare, olmesartan-associated condition; discontinue and evaluate promptly if unexplained severe diarrhea and weight loss occur.

Hypotension: Symptomatic hypotension may occur, particularly in patients with volume or salt depletion (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting); correct volume depletion before starting Belsar-M 5 mg+20 mg.

Renal function/hyperkalemia: Monitor renal function and serum potassium periodically, especially in patients with renal impairment, diabetes, or those on concomitant potassium-sparing agents; changes in renal function including acute renal failure can occur, especially in patients whose renal function depends on the renin-angiotensin system (e.g., renal artery stenosis, severe heart failure).

Hepatic impairment: Use with caution; monitor closely, as amlodipine plasma concentrations increase in hepatic impairment.

Increased angina or myocardial infarction: Rarely, patients with severe obstructive coronary artery disease may develop increased frequency, duration, or severity of angina on starting therapy or at the time of dosage increase.

Overdose of Belsar-M 5 mg+20 mg may cause excessive peripheral vasodilation with marked hypotension, reflex tachycardia, and possibly shock. If overdose is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt home treatment. Treatment is generally supportive, including monitoring of cardiac and respiratory function, elevation of the extremities, and attention to circulating fluid volume, under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No initial dosage adjustment is required in mild-to-moderate renal impairment; use Belsar-M 5 mg+20 mg with caution and monitor renal function and potassium in patients with severe renal impairment. Not studied in patients on dialysis.

Hepatic impairment: Initiate at the lowest recommended amlodipine dose; the olmesartan component should be used with caution, as no formal dosage adjustment has been established.

Elderly: No overall differences in effectiveness observed; elderly patients may be more sensitive to blood-pressure-lowering effects, so caution is advised.

Pediatric use: See Pediatric Uses.

Black patients: Antihypertensive effect of ARBs, including olmesartan, may be somewhat less than in non-Black patients; combination with a calcium channel blocker (as in this product) can help address this.

Belsar-M 5 mg+20 mg is generally used as a long-term, ongoing treatment for chronic hypertension. It does not cure high blood pressure and must be continued indefinitely, as directed by a physician, along with regular blood pressure monitoring and periodic laboratory tests (renal function, electrolytes). Do not stop taking this medicine abruptly without medical advice, even if blood pressure normalizes, as this may lead to a rebound rise in blood pressure.

Belsar-M 5 mg+20 mg is a fixed-dose combination of a Dihydropyridine Calcium Channel Blocker (amlodipine) and an Angiotensin II Receptor Blocker/ARB (olmesartan medoxomil).

Belsar-M 5 mg+20 mg lowers blood pressure via two complementary mechanisms: amlodipine blocks L-type calcium channels in vascular smooth muscle, reducing calcium influx and causing vasodilation; olmesartan selectively and competitively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone release. Together these mechanisms produce a greater reduction in peripheral vascular resistance and blood pressure than either agent alone.

D (FDA legacy classification for angiotensin II receptor blocker-containing products; historically categorized as Category C in the first trimester and Category D in the second and third trimesters due to fetal toxicity)

The safety and effectiveness of Belsar-M 5 mg+20 mg as a fixed-dose combination have not been established in pediatric patients (below 18 years of age). This combination product is not recommended for use in children. If antihypertensive therapy is required in a pediatric patient, a physician should select an agent appropriately studied for pediatric use.